These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1073 related items for PubMed ID: 18423260

  • 1. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
    Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R.
    J Am Acad Dermatol; 2008 May; 58(5):826-50. PubMed ID: 18423260
    [Abstract] [Full Text] [Related]

  • 2. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
    Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A.
    J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
    [Abstract] [Full Text] [Related]

  • 3. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.
    Weger W.
    Br J Pharmacol; 2010 Jun; 160(4):810-20. PubMed ID: 20590580
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Biological agents in treatment of psoriatic arthritis].
    Lewicki M, Dutkiewicz B, Widuchowska M, Kucharz EJ.
    Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options.
    Leon A, Nguyen A, Letsinger J, Koo J.
    Expert Opin Pharmacother; 2007 Apr; 8(5):617-32. PubMed ID: 17376017
    [Abstract] [Full Text] [Related]

  • 8. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
    Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM.
    J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
    [Abstract] [Full Text] [Related]

  • 9. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM, Kirby B.
    BioDrugs; 2005 Jan; 19(1):47-57. PubMed ID: 15691217
    [Abstract] [Full Text] [Related]

  • 10. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M, Costanzo A.
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R.
    J Am Acad Dermatol; 2009 Sep; 61(3):451-85. PubMed ID: 19493586
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM, Bottino CJ, Lindholm J, Buchholz R.
    J Drugs Dermatol; 2005 Sep; 4(5):544-55. PubMed ID: 16167412
    [Abstract] [Full Text] [Related]

  • 18. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [Abstract] [Full Text] [Related]

  • 19. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
    Papp KA, Dekoven J, Parsons L, Pirzada S, Robern M, Robertson L, Tan JK.
    J Cutan Med Surg; 2012 Sep; 16(3):153-68. PubMed ID: 22713438
    [Abstract] [Full Text] [Related]

  • 20. Biologics and Psoriasis: The Beat Goes On.
    Kim HJ, Lebwohl MG.
    Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.